Vivo Capital’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Vivo Capital’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-146,426	Closed	-$71K	–	54
2022 Q3	$71K	Hold	146,426	–	–	0.01%	51
2022 Q2	$73K	Hold	146,426	–	–	0.01%	49
2022 Q1	$89K	Hold	146,426	–	–	0.01%	53
2021 Q4	$99K	Hold	146,426	–	–	0.01%	54
2021 Q3	$502K	Hold	146,426	–	–	0.02%	60
2021 Q2	$556K	Hold	146,426	–	–	0.02%	59
2021 Q1	$908K	Hold	146,426	–	–	0.03%	63
2020 Q4	$1.15M	Hold	146,426	–	–	0.05%	58
2020 Q3	$1.5M	Buy	+146,426	New	+$1.5M	0.09%	63

Other funds holding MTCR

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vivo Capital's MTCR Position: Q4 2022 in Review

Vivo Capital sold out of Metacrine, Inc. Common Stock (MTCR) in Q4 2022, closing a stake of 146,426 shares — an estimated $71K sold.

Vivo Capital first reported a position in MTCR in Q3 2020 and held it in 9 quarters. The position peaked at $1.5M in Q3 2020. 29 funds tracked by Wall St. Rank hold MTCR as of Q4 2022.

Vivo Capital reported no remaining Metacrine, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Vivo Capital sold 146,426 Metacrine, Inc. Common Stock shares in Q4 2022, an estimated $71K.
Vivo Capital first reported a position in Metacrine, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
Vivo Capital's Metacrine, Inc. Common Stock position peaked at $1.5M in Q3 2020.
29 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q4 2022.

Based on Vivo Capital's 13F filing for Q4 2022, filed 13 Feb 2023.